ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Two contract manufacturers of biologic drugs plan significant investments in the US. Fujifilm says it will spend more than $2 billion to establish a large-scale cell culture site in the US by 2025. The Japanese firm is already spending almost $1 billion to double the size of a biologics plant in Denmark that it acquired from Biogen. Meanwhile, the British firm Abzena plans to build its sixth biologics plant, this one in the US.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X